MandellGL. Cephalosporins. In: MandellGLDouglasRGBennettJE, eds. Principles and practice of infectious
diseases. 2nd ed. New
York: John Wiley & Sons,
1985: 180–7.
2.
MandellGLSandeMA. Antimicrobial agents: Penicillins, cephalosporins,
and other beta-lactam antibiotics. In: GilmanAGGoodmanLSRallTWMuradF, eds. Goodman and Gilman's the pharmacological basis of
therapeutics. 7th ed.New York: Macmillan,
1985: 1115–37.
3.
SandersCCSandersWE. Emergence of resistance during therapy with the newer
beta-lactam antibiotics: Role of inducible beta-lactamases and implications for
the future. Rev Infect Dis1983; 5:
639–48.
4.
SandersCC. Novel resistance selected by the new expanded
spectrum cephalosporins: A concern. J Infect Dis1983; 147:
585–9.
5.
BarriereSL. Therapeutic considerations in using combinations of
newer beta-lactam antibiotics. Clin Pharm1986; 5:
24–33.
6.
FarrarWEJrGramlingPK. Antistaphylococcal activity and beta-lactamase
resistance of newer cephalosporins. J Infect Dis1976; 133:
691–5.
7.
RegameyCLibkeRDEngelkingER. Inactivation of cefazolin, cephaloridine, and
cephalothin by methicillin-sensitive and methicillin-resistant strains of
Staphylococcus aureus. J Infect Dis1975; 131:
291–4.
8.
TurckM. Cephalosporins and related antibiotics: An
overview. Rev Infect Dis1983; 4:
S281–7.
9.
QuintilianiRNightingaleCH. Cefazolin. Ann Intern
Med1978; 89:
650–6.
10.
McEvoyGKMcQuarrieGM, eds. American Hospital Formulary Service drug information
88. Bethesda, MD: American
Society of Hospital Pharmacists,
1988.
ReeseREBettsRF. Antibiotic use. In: ReeseREDouglasRGJr, eds. A practical approach to infectious diseases.
2nd ed.Boston: Little,
Brown, 1986:
574–8.
14.
BurnakisTG. Surgical antimicrobial prophylaxis: Principles and
guidelines. Pharmacotherapy1984; 4:
248–71.
15.
DipiroJTBivinsBARecordKE. The prophylactic use of antimicrobials in
surgery. Curr Prob Surg1983; 20:
76–132.
16.
Antimicrobial prophylaxis in surgery. Med Lett
Drugs Ther1987; 29:
91–4.
17.
KaiserAB. Antimicrobial prophylaxis in surgery.
N Engl J Med1986; 315:
1129–38.
18.
BurkeJF. Preventing bacterial infection by coordinating
antibiotic and host activity: A time-dependent relationship.
South Med J1977; 70 (suppl 1):
24–6.
19.
StoneHHHaneyBBKolbLDGeheberCEHooperCA. Prophylactic and preventive antibiotic therapy:
Timing, duration, and economics. Ann Surg1979; 189:
691–9.
20.
ConteJEJrBarriereSL. Manual of antibiotics and infectious diseases.
5th ed.Philadelphia: Lea &
Febiger, 1984:
145–7.
21.
SaxonABeallGNRohrASAdelmanDC. Immediate hyper-sensitivity reactions to beta-lactam
antibiotics. Ann Intern Med1987; 107:
204–15.
22.
Cefuroxime axetil. Med Lett Drugs
Ther1988; 30:
57–9.
23.
DiasMB SouzaJacobusNVTallyFPGorbachSL. Activity of cefotetan against anaerobic
bacteria. Diagn Microbiol Infect Dis1986; 4:
359–63.
24.
AldridgeKESandersCVJanneyA. Comparison of the activities of penicillin G and new
beta-lactam antibiotics against clinical isolates of Bacteroides
species. Antimicrob Agents Chemother1984; 26:
410–3.
25.
WardARichardsDM. Cefotetan. A review of its antibacterial activity,
pharmacokinetic properties and therapeutic uses.
Drugs1985; 30:
382–426.
26.
GorbachSL. Bacteroides species. In: MandellGLDouglasRGJrBennettJE, eds. Principles and practice of infectious
diseases. 2nd ed.New York: John Wiley &
Sons, 1985:
1370–1.
27.
McGowanKGorbachSL. Anaerobes in mixed infections.
J Infect Dis1981; 144:
181–6.
28.
WexlerHMHarrisBCarterWT. Six-year retrospective survey of resistance of
Bacteroides fragilis group species to clindamycin and
cefoxitin. Diagn Microbiol Infect Dis1986; 4:
247–53.
29.
TartaglioneTAPolkRE. Review of the new second-generation cephalosporins:
Cefonicid, ceforanide, and cefuroxime. Drug Intell Clin
Pharm1985; 19:
188–98.
30.
GoldBRodriguezWJ. Cefuroxime: Mechanisms of action, antimicrobial
activity, pharmacokinetics, clinical applications, adverse reactions and
therapeutic indications. Pharmacotherapy1983; 3:
82–100.
31.
PontzerREKayeD. Cefonicid: A long-acting, second-generation
cephalosporin. Antimicrobial activity, pharmacokinetics, clinical efficacy and
adverse effects. Pharmacotherapy1984; 4:
325–33.
GleckmanRARothRM. Community-acquired bacterial pneumonia in the
elderly. Pharmacotherapy1984; 4:
81–8.
34.
SlamaTGSklarSJMisinskiJFessSW. Randomized comparison of cefamandole, cefazolin, and
cefuroxime prophylaxis in open-heart surgery. Antimicrob
Agents Chemother1986; 29:
744–7.
35.
McGregorJAFrenchJIMakowskiE. Single-dose cefotetan versus multidose cefoxitin for
prophylaxis in cesarean section in high-risk patients. Am
J Obstet Gynecol1986; 154:
955–60.
36.
VarnerMWWeinerCPPetzoldRGalaskRP. Comparison of cefotetan and cefoxitin as prophylaxis
in cesarean section. Am J Obstet Gynecol1986; 154:
951–4.
37.
OrrJWVarnerREKilgoreLC. Cefotetan versus cefoxitin as prophylaxis in
hysterectomy. Am J Obstet Gynecol1986; 154:
960–3.
38.
HemsellDLBawdonREHemsellPG. Single-dose cephalosporin for prevention of major
pelvic infection after vaginal hysterectomy: Cefazolin versus cefoxitin versus
cefotaxime. Am J Obstet Gynecol1987; 156:
1201–5.
39.
Professional information brochure.
Cefotan (cefotetan disodium). Wilmington,
DE: Stuart Pharmaceuticals,
1986.
40.
PoindexterANIIISweetRRitterM. Cefotetan in the treatment of obstetric and
gynecologic infections. Am J Obstet Gynecol1986; 154:
946–50.
41.
KnuppelRAO'BryanDLakeM. Cefotetan: Comparative and noncomparative studies in
obstetric and gynecologic infections. South Med J1988; 81:
185–8.
42.
LipskyJ. N-methylthiotetrazole inhibition of the gamma
carboxylation of glutamic acid: Possible mechanism for antibiotic associated
hypoprothrombinemia. Lancet1983; 2:
192–3.
43.
SchentagJJWelageLSGraselaTHAdelmanMH. Determinants of antibiotic-associated
hypoprothrombinemia. Pharmacotherapy1987; 7:
80–6.
44.
SattlerFRWeitekampMRBallardJO. Potential for bleeding with the new beta-lactam
antibiotics. Ann Intern Med1986; 105:
924–31.
45.
BrownRBKlarJLemeshowS. Enhanced bleeding with cefoxitin or moxalactam.
Statistical analysis within a defined population of 1493 patients.
Arch Intern Med1986; 146:
2159–64.
